Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$24.46 USD
-0.03 (-0.12%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $24.43 -0.03 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for Mirum Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 286 | 152 | 157 | 232 | 117 |
Receivables | 68 | 24 | 3 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 22 | 6 | 2 | 0 | 0 |
Other Current Assets | 11 | 9 | 5 | 5 | 3 |
Total Current Assets | 388 | 190 | 167 | 236 | 119 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 5 | 0 | 23 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 253 | 59 | 19 | 0 | 0 |
Deposits & Other Assets | 4 | 101 | 102 | 1 | 0 |
Total Assets | 647 | 353 | 295 | 241 | 147 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 9 | 9 | 3 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 79 | 54 | 31 | 13 | 9 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 2 | 1 | 0 |
Total Current Liabilities | 87 | 65 | 43 | 18 | 13 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 306 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 145 | 130 | 48 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 398 | 211 | 174 | 69 | 16 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 803 | 535 | 377 | 345 | 200 |
Retained Earnings | -556 | -393 | -257 | -173 | -70 |
Other Equity | 2 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 249 | 142 | 120 | 172 | 130 |
Total Liabilities & Shareholder's Equity | 647 | 353 | 295 | 241 | 147 |
Total Common Equity | 249 | 142 | 120 | 172 | 130 |
Shares Outstanding | 46.60 | 36.80 | 30.60 | 25.70 | 22.90 |
Book Value Per Share | 5.34 | 3.86 | 3.93 | 6.70 | 5.69 |
Fiscal Year End for Mirum Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 286 | 306 | 330 | 132 |
Receivables | NA | 68 | 48 | 35 | 25 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 22 | 22 | 9 | 7 |
Other Current Assets | NA | 11 | 12 | 10 | 9 |
Total Current Assets | NA | 388 | 389 | 384 | 172 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 253 | 258 | 56 | 58 |
Deposits & Other Assets | NA | 4 | 2 | 1 | 101 |
Total Assets | NA | 647 | 651 | 444 | 334 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 7 | 7 | 14 | 6 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 79 | 66 | 43 | 40 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 1 |
Total Current Liabilities | NA | 87 | 75 | 58 | 49 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 306 | 306 | 306 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 142 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 398 | 382 | 365 | 192 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 803 | 791 | 576 | 564 |
Retained Earnings | NA | -556 | -521 | -497 | -423 |
Other Equity | NA | 2 | -1 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 249 | 269 | 79 | 141 |
Total Liabilities & Shareholder's Equity | NA | 647 | 651 | 444 | 334 |
Total Common Equity | 0 | 249 | 269 | 79 | 141 |
Shares Outstanding | 47.00 | 46.60 | 46.60 | 38.30 | 38.00 |
Book Value Per Share | 0.00 | 5.34 | 5.77 | 2.05 | 3.71 |